ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AstraZeneca pushes into genomics

by Michael McCoy
April 25, 2016 | APPEARED IN VOLUME 94, ISSUE 17

AstraZeneca is launching an effort to incorporate genomics into drug discovery and development. The British drugmaker plans to access 500,000 genome sequences donated by its clinical trial participants and share them with Human Longevity. In exchange it will get access to Human Longevity’s database of up to 1 million genomic and health records. The company will create an in-house Centre for Genomics Research. And it will work with Finland’s Institute for Molecular Medicine to study genes of interest in the Finnish population, which carries a higher-than-normal frequency of rare variants.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment